Peregrine Capital Management LLC Cuts Stake in Edwards Lifesciences Co. (NYSE:EW)

Peregrine Capital Management LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 407,829 shares of the medical research company's stock after selling 15,814 shares during the quarter. Edwards Lifesciences comprises 0.9% of Peregrine Capital Management LLC's portfolio, making the stock its 24th largest position. Peregrine Capital Management LLC owned approximately 0.07% of Edwards Lifesciences worth $31,097,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company's stock worth $3,577,163,000 after purchasing an additional 325,808 shares in the last quarter. Alliancebernstein L.P. increased its position in Edwards Lifesciences by 0.3% during the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company's stock valued at $1,934,919,000 after purchasing an additional 66,763 shares during the period. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company's stock worth $1,138,575,000 after buying an additional 1,390,427 shares during the last quarter. Moneta Group Investment Advisors LLC grew its position in shares of Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock worth $1,148,938,000 after buying an additional 15,384,593 shares during the last quarter. Finally, Brown Advisory Inc. boosted its stake in Edwards Lifesciences by 5.7% in the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company's stock worth $1,048,424,000 after purchasing an additional 818,849 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. OTR Global upgraded shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Truist Financial increased their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, December 22nd. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an "overweight" rating in a research note on Thursday, March 21st. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. Finally, Citigroup increased their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $90.67.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 1,715 shares of the company's stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the completion of the transaction, the vice president now directly owns 17,213 shares of the company's stock, valued at $1,566,038.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now owns 17,213 shares in the company, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Insiders sold a total of 204,004 shares of company stock valued at $17,922,954 over the last three months. Company insiders own 1.27% of the company's stock.

Edwards Lifesciences Stock Up 0.8 %

Shares of EW traded up $0.71 during midday trading on Tuesday, reaching $93.05. 2,631,109 shares of the stock were exchanged, compared to its average volume of 3,969,763. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm has a 50 day simple moving average of $89.03 and a 200-day simple moving average of $77.18. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The company has a market cap of $56.01 billion, a price-to-earnings ratio of 40.46, a P/E/G ratio of 4.59 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the firm posted $0.64 EPS. The company's revenue was up 13.3% on a year-over-year basis. Research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.